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Abstract
Background: Smoking is the most important reversible cardiovascular risk factor. It is well established that quitting
smoking reduces coronary events. However, on several occasions, the cardiovascular safety of smoking cessation
drugs has been questioned. Our goal is to evaluate the effects of smoking cessation drugs on blood pressure and
heart rate in patients from a smoking cessation service in a cardiology hospital.
Methods: We examined the PAF database (Smoking Cessation Assistance Program database) between January
2008 and March 2014. We analyzed data from 900 patients who were compliant with the treatment (50.5 % male,
average age 53 ± 17 years). The most frequent clinical diagnoses were coronary artery disease (25.2 %), hypertension
(57.2 %), and diabetes (13.4 %). Blood pressure, heart rate, and carbon monoxide (CO) concentration in exhaled air
were analyzed at consecutive visits during the first 45 days of treatment (mean visits - 3). Analysis of repeated measures
was used for the statistical analysis (p < 0.05).
Results: Two hundred seventy one patients used nicotine replacement therapy (NRT) alone, 81 used bupropion alone,
154 used varenicline alone, 283 used NRT plus bupropion and 111 used bupropion plus varenicline. For all smoking
cessation drugs, used alone or in combination, no increase occurred in the average value of systolic blood pressure
(SBP), diastolic blood pressure (DBP) and heart rate (HR). Significant reductions in CO concentrations occurred in all
smoking cessation drug groups.
Conclusion: Smoking cessation drugs used in monotherapy or in combined regimens did not influence systolic blood
pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in this group of patients during the observation period.
Keywords: Smoking cessation, Nicotine replacement therapy, Bupropion, Varenicline, Cardiovascular disease,
Hypertension
Background
Smoking cessation substantially lowers the risk of death
in patients of all ages [1], including those with cardiovas-
cular disease [2]. The long-term cardiovascular benefits
of smoking cessation are well established [1, 2]. Clinical
practice guidelines [3] recommend the use of cessation
pharmacotherapy for smokers interested in quitting. The
first-line drugs for smoking cessation are nicotine re-
placement therapy (NRT - gum or patch), bupropion
(Zyban, Wellbutrin) and varenicline (Chantix, Champix).
These medications demonstrated effectiveness in
achieving complete smoking cessation [3], but their safety
in patients with cardiovascular (CV) disease has been
questioned and evaluated in several studies and meta-
analyses. Previous reports associated NRT use with oc-
currence of cardiovascular events, such as myocardial
infarction, especially in patients who continued smoking
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[4]. However, two recent meta-analyses showed an in-
crease in CV symptoms, including tachycardia and non-
specific chest pain [5, 6] but not in MACEs - defined as
cardiovascular death, nonfatal myocardial infarction and
nonfatal stroke [6]. With bupropion, trials including
smokers with cardiovascular disease did not report a sta-
tistically significant increase in CV events compared to
placebo. However, the sample sizes were small and not
powered for safety [7–9].
A recent network meta-analysis of 21 randomized clin-
ical trials (RCTs) showed that bupropion was not harmful
for MACEs and appeared to have a cardioprotective effect
[6]. Varenicline, an alpha-4 beta-2 nicotinic acetylcholine
receptor partial agonist, binds to the same receptors as
nicotine, which is known to have sympathomimetic car-
diovascular effects [10]. The first meta-analysis on the CV
safety of varenicline, predominantly composed of trials
excluding patients with CV disease, concluded that in-
creased risk (72 %) exists for minor and major cardiovas-
cular events among tobacco users [11]. A more recent
large meta-analysis with more than 9,000 patients, how-
ever, found no significant risk of major CV events associ-
ated with varenicline use [6, 12]. Trials that included
patients with a history of CV disease found that even in a
higher risk population, varenicline did not add significant
damage [6, 12].
There are few studies evaluating combination of ther-
apies for smoking cessation [13–15], none of them
evaluating safety in patients with cardiovascular disease.
One of these studies excluded patients with cardiovascu-
lar diseases or history of hypertension [15]. In the other
studies there were not reports of major or minor adverse
cardiovascular events during the smoking cessation ther-
apy [13, 14]. There is not meta-analysis available in the
literature until this moment.
We examined CV effects of these drugs on blood pres-
sure and heart rate in outpatient setting according to
different combination therapies and the previous pres-
ence of hypertension, coronary artery disease, and/or
acute myocardial infarction.
Methods
We analyzed 900 outpatient subjects followed at the
Smoking Cessation Program of the Heart Institute
(InCor), University of Sao Paulo Medical School, Sao
Paulo, Brazil. Most of the patients have cardiovascular dis-
eases or high risk score. We used the PAF database
(Smokers Assistance Program) between January 2008 and
March 2014 and looked up subjects of both genders older
than 18 years of age. The Ethics Committee for Research
Project Evaluation (CAPPesq) of the Hospital das Clinicas –
School of Medicine, University of Sao Paulo, approved the
study. The study complied with the Declaration of
Helsinki. They agreed with the informed consent form.
During the study period, 1791 patients were enrolled
to the service. However, 891 patients were excluded be-
cause they did not come in the consecutive visits and
their data for BP, HR, and/or CO were not available.
However, patients with analyzed data (n = 900) did not
have significant differences in their SBP, DBP, HR and
CO values (125 ± 21 mmHg; 76 ± 12 mmHg; 74 ± 13 bpm;
11 ± 10 ppm) compared with data of the untreated pa-
tients (n = 891) (123 ± 22 mmHg; 74 ± 18 mmHg; 74 ±
18 bpm; 12 ± 12 ppm) (p > 0.05).
Thus, 900 patients were included in this analysis. They
received smoking cessation medication to be taken for at
least 12 weeks. Among the available medications, there
were nicotine replacement therapies (NRT — patch and
gum), bupropion, and varenicline. In the first visit (base-
line), the patient was not in use of any drug for smoking
cessation. One of these drugs was prescribed as mono-
therapy according to the nicotine dependence level, pre-
vious use of smoking cessation drugs, availability of the
medication and lack of absolute contraindication related
to each drug. Varenicline was prescribed for patients
who failed in previous attempts with NRT and/or bupro-
pion, or who smoked one or more packs of cigarettes
per day.
The gap between follow-up visits was 2 to 3 weeks. In
all visits the patient were questioned about smoking sta-
tus, compliance and collateral effects of the medication
prescribed, and we evaluated the vital signs, CO level,
and withdrawal symptoms.
In the second visit, the patients who achieved success
with monotherapy and had no or mild withdrawal symp-
toms were kept with the same medication. The patients
who did not achieve success and the patients who
achieved complete cessation but with moderate or intense
withdrawal symptoms had associated therapies [13].
The data were categorized in 3 visits in sequential
follow-up, called initial (baseline), second, and third
visits. Variables from the database included in the ana-
lysis were: age; sex; smoking cessation; smoking cessa-
tion drugs used; smoker’s degree of nicotine dependence
according to the Fagerström score [16] and Issa score
[17] at the initial visit; presence or absence of hyperten-
sion, diabetes mellitus type 2 (DMT2) and coronary ar-
tery disease (CAD); acute myocardial infarction (AMI);
obesity, heart failure, arrhythmias, or valvular heart dis-
ease; and the number of cardiovascular medications
being used at the initial visit. All the visits and measure-
ments were done during the afternoon period. In each
visit, the median of 2 blood pressures was taken with a
mercury sphygmomanometer, and heart rate and ex-
haled CO level were collected. The parameter we used
for smoking cessation was CO level below 6 ppm [18]
associated with the self-reported cessation. The data re-
garding systolic blood pressure (SBP), diastolic blood
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pressure (DBP), and heart rate (HR) of study patients
were compared for initial, second, and third visits, ac-
cording to smoking cessation drugs used, alone or in
combination, as well as between 2 groups: first with the
presence of hypertension, CAD, and/or AMI and second
without all these diseases.
Statistical analysis
Categorical variables are presented as percentages and
continuous variables are presented as means ± SD (stand-
ard deviation). Friedman’s test (repeated measures) was
performed to analyze SBP, DBP, HR, and CO levels during
visits, according to the prescribed pharmacotherapy and
the presence of hypertension, CAD, or AMI. Friedman’s
test was also performed to analyze SBP, DBP, and HR ac-
cording with the CO cutoff (6 ppm) in the second and
third visits and the presence of hypertension, CAD, or
AMI. Statistical analyses were carried out using SPSS 16.0
software (IBM, New York, NY), with the level of signifi-
cance set at p < 0.05.
Results
During the study, 900 patients were included in the ana-
lysis. The median age of patients was 53 ± 17 and 50.5 %
were male. Table 1 shows demographic and clinical char-
acteristics. Smoker’s degree of nicotine dependence was
6.3 ± 2.3 assessed by Fagerström score [16] and 2.9 ± 0.9
by Issa score [17]. From the 900 patients included, 580
(64.4 %) had hypertension, CAD, and/or AMI. Hyperten-
sion was the most common cardiovascular disease
(57.2 %), and a significant number of patients had coron-
ary artery disease (25.2 %) and previous acute myocar-
dial infarction (27.0 %).
Among these 900 patients, 271 patients used NRT
alone, 81 used bupropion alone, 154 used varenicline
alone, 283 used NRT + bupropion, and 111 used bupro-
pion + varenicline.
Table 2 shows the sequential measures of blood pres-
sures, heart rate and CO concentration of patients accord-
ing to prescribed drugs and the presence of hypertension,
CAD, or AMI. We observed that SBP, DBP, and HR did
not change significantly (p > 0.05) during 3 sequential
measures in follow-up, regardless of pharmacotherapy for
smoking cessation used and the presence of hypertension,
CAD, and/or previous AMI. The CO analysis showed a
significant reduction (p < 0.001) in exhaled CO level in 3
sequential measures in follow-up in all the types of
pharmacotherapy for smoking cessation used, alone or in
combination.
We also analyzed BP and HR of followed patients
(n = 900) according with a CO cutoff of 6 ppm in the sec-
ond and third visits and the presence of hypertension,
CAD, or AMI. There was no significant influence of this
variable in change BP and HR in all smoking cessation
drugs group.
Discussion
It is well known that quitting smoking can reduce the
risk of mortality from heart disease and acute myocar-
dial infarction [2]. However, studies regarding CV risks
associated with pharmacotherapies for smoking cessation
have been concerned with public health. Few randomized
controlled trials have been conducted in populations with
high cardiovascular risk profiles and also few trials have
compared head-to-head the safety of smoking cessation
medications.
We did not observe any significant change in systolic
or diastolic blood pressure and heart rate in 900 patients
who used smoking cessation therapies and were followed
at Heart Institute, a cardiac hospital with a large rate of
patients with hypertension, CAD, and/or AMI. This re-
sult was regardless of the combination of pharmacother-
apies used in the smoking cessation treatment and the
presence or absence of cited comorbidities.
In the literature, tachycardia is a well-established and
benign adverse effect observed in a lot of studies using
NRT [5]. Some studies showed an increase in HR (10–
15 beats/min) and blood pressure (5–10 mmHg) after
NRT use [19, 20], even in smokers who interrupted to-
bacco consumption [20]. A recent meta-analysis showed
similar results - an association of using NRT and in-
creasing minor CV events, mainly due to the occurrence
of tachycardia, but without adding risk to major CV
events [6]. In patients with a history of a predisposing
high-risk condition, in a smaller sample, this was not
found [6]. The development of tolerance to blood pres-
sure effects of nicotine in heavy smokers can be included
in these divergent hemodynamic findings.
Concerning bupropion, an increase in blood pressure
could be an important cardiovascular side effect, regard-
less of pre-existing hypertension, because of the effect of
bupropion on the reuptake of norepinephrine [21]. How-
ever, this effect is not seen overall in clinical practice
and our results are in accordance with the results from
Table 1 Demographic and clinical characteristics of study patients
Variables n = 900
Sex, female (%) 49.5
Fagerström score 6.3 ± 2.3
Issa score 2.9 ± 0.9
Hypertension (%) 57.2
Coronary artery disease (%) 25.2
Acute myocardial infarction (%) 27.0
Diabetes mellitus type 2 (%) 13.4
Obesity (%) 9.1
Number of medicines 3.6 ± 3.4
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Table 2 Sequential measures of blood pressures, heart rate, and
monoximetria of patients according to prescribed drugs and
the presence of hypertension, CAD, or AMI
Varenicline
Presence of hypertension, CAD, or AMI
Variables No (n = 85) Yes (n = 69)
Initial SBP (mmHg) 118 ± 14 131 ± 21
Second visit SBP (mmHg) 117 ± 13 127 ± 20
Third visit SBP (mmHg) 117 ± 15 128 ± 19
p value 0.20 0.10
Initial DBP (mmHg) 76 ± 10 81 ± 12
Second visit DBP (mmHg) 74 ± 8 78 ± 10
Third visit DBP (mmHg) 76 ± 10 79 ± 11
p value 0.26 0.16
Initial HR (bpm) 76 ± 11 76 ± 10
Second visit HR (bpm) 75 ± 9 76 ± 10
Third visit HR (bpm) 75 ± 8 74 ± 10
p value 0.60 0.30
Initial monoximetria (ppm) 15 ± 11 12 ± 7
Second visit monoximetria (ppm) 8 ± 10 7 ± 6
Third visit monoximetria (ppm) 4 ± 9 4 ± 5
p value <0.001 <0.001
Varenicline Plus Bupropione
Presence of hypertension, CAD, or AMI
Variables No (n = 62) Yes (n = 49)
Initial SBP (mmHg) 117 ± 14 128 ± 18
Second visit SBP (mmHg) 117 ± 15 126 ± 21
Third visit SBP (mmHg) 115 ± 15 129 ± 21
p value 0.56 0.63
Initial DBP (mmHg) 75 ± 8 81 ± 12
Second visit DBP (mmHg) 74 ± 8 81 ± 12
Third visit DBP (mmHg) 74 ± 8 81 ± 11
p value 0.85 0.27
Initial HR (bpm) 79 ± 10 73 ± 10
Second visit HR (bpm) 74 ± 13 73 ± 10
Third visit HR (bpm) 77 ± 10 73 ± 11
p value 0.06 0.86
Initial monoximetria (ppm) 17 ± 10 16 ± 8
Second visit monoximetria (ppm) 11 ± 10 10 ± 7
Third visit monoximetria (ppm) 7 ± 7 9 ± 8
p value <0.001 <0.001
Table 2 Sequential measures of blood pressures, heart rate, and
monoximetria of patients according to prescribed drugs and
the presence of hypertension, CAD, or AMI (Continued)
Bupropione
Presence of hypertension, CAD, or AMI
Variables No (n = 39) Yes (n = 42)
Initial SBP (mmHg) 112 ± 14 132 ± 27
Second visit SBP (mmHg) 117 ± 17 126 ± 23
Third visit SBP (mmHg) 116 ± 15 132 ± 28
p value 0.12 0.31
Initial DBP (mmHg) 74 ± 7 81 ± 12
Second visit DBP (mmHg) 76 ± 10 78 ± 10
Third visit DBP (mmHg) 76 ± 9 82 ± 11
p value 0.63 0.14
Initial HR (bpm) 76 ± 10 73 ± 13
Second visit HR (bpm) 76 ± 8 73 ± 14
Third visit HR (bpm) 75 ± 9 74 ± 14
p value 0.25 0.99
Initial monoximetria (ppm) 14 ± 13 12 ± 11
Second visit monoximetria (ppm) 7 ± 10 8 ± 6
Third visit monoximetria (ppm) 6 ± 8 7 ± 6
p value <0.001 <0.001
Bupropione Plus NRT
Presence of hypertension, CAD, or AMI
Variables No (n = 72) Yes (n = 211)
Initial SBP (mmHg) 117 ± 16 132 ± 21
Second visit SBP (mmHg) 117 ± 18 134 ± 22
Third visit SBP (mmHg) 118 ± 18 132 ± 21
p value 0.89 0.53
Initial DBP (mmHg) 73 ± 10 80 ± 12
Second visit DBP (mmHg) 73 ± 11 79 ± 13
Third visit DBP (mmHg) 74 ± 11 80 ± 13
p value 0.67 0.81
Initial HR (bpm) 76 ± 11 73 ± 14
Second visit HR (bpm) 75 ± 13 74 ± 12
Third visit HR (bpm) 75 ± 11 74 ± 13
p value 0.87 0.83
Initial monoximetria (ppm) 11 ± 7 11 ± 8
Second visit monoximetria (ppm) 7 ± 6 7 ± 8
Third visit monoximetria (ppm) 5 ± 6 5 ± 5
p value <0.001 <0.001
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other studies. Settle et al, enrolling more than 500 pa-
tients with depression, did not show clinically important
effects on BP or HR when bupropion was compared
with placebo [22]. In patients with CV diseases, a ran-
domized trial including 248 smokers hospitalized be-
cause of CAD did not find a significant change in blood
pressure after 12 weeks of slow release (SR) bupropion
compared with placebo [7]. A clinical trial with 629 per-
sistent smokers with CV disease, in which nearly half
had experienced an AMI previously, evaluated bupro-
pion versus placebo and did not find significant changes
in BP or HR. Patients with baseline BP ≥ 160/100 mmHg
were excluded [8]. In another study with 300 outpatient
smokers with untreated stage 1 hypertension, different
doses of bupropion induced a small reduction in BP, and
bupropion 400 mg SR also increased heart rate by 2.9
beats/min versus placebo [23]. On the other hand, stud-
ies by Roose et al with small samples observed that bu-
propion can increase sympathomimetic activity and
increase HR and BP in patients with depression and
heart disease if it is used in higher doses [24, 25].
In the same way, Tonstad et al reported no changes in
BP after 24 weeks of varenicline versus placebo. The
mean HR remained similar in the varenicline group and
decreased by 2 beats per minute in the placebo group
[26]. Additionally, a randomized trial with 714 smokers
with stable CV disease (history of myocardial infarction,
coronary revascularization, angina pectoris, peripheral ar-
terial vascular disease, stroke or transient ischemic attack)
showed a 0.5 mmHg increase in SBP and no changes in
DBP and HR in the varenicline group versus placebo [10].
There are some studies with the use of NRT in popu-
lation of smokers without cardiovascular diseases or
with hypertension alone [27, 28], which did not find
changes in HR and BP.
This study has some limitations. BP and HR were
measured at 3 consecutive visits. Therefore, although it
is enough to have a comparison, possible small changes
might be seen in a more prolonged follow. Compliance
with the treatment and smoking status were measured
during the follow-up period by asking patients and by
measuring exhaled CO level, which showed a significant
reduction in comparison with basal CO level, regardless
of pharmacotherapy used. It indicates reduction or ces-
sation of smoking. We did not design a study with the
objective and power to observe major CV events.
Our findings of maintenance of BP and HR in a rela-
tively large population of smokers with and without pre-
existing stable CV diseases using different combinations
of smoking cessation therapies are important as a safety
data for clinical practice. This result is in agreement with
a recent meta-analysis of the use of NRT, bupropion and
varenicline, which did not find an increase in major CV
events with all drugs [6]. In patients with CV diseases,
the existing data do not suggest harm and the benefits
of smoking cessation in the long term exceeds an even-
tual small risk associated with pharmacotherapy drugs
for smoking cessation.
Conclusion
Our data from a real clinical practice suggest that, even in
patients with hypertension, CAD, and/or AMI, there are
no significant clinical change in blood pressure or heart
rate during the use of NRT, varenicline, and/or bupropion.
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